Surrozen, Inc./DE

Churchill Capital Corp VII, trading under the ticker CHFW, was a blank-check company sponsored by Churchill Capital and completed its initial public offering in 2021. The SPAC targeted the healthcare and biotechnology sector, with a focus on life sciences. In April 2021, CHFW filed an 8-K with the SEC disclosing a definitive business combination agreement with Surrozen, Inc., a South San Francisco-based biopharmaceutical company developing Wnt pathway-activating antibodies for organ repair and regeneration. The transaction subsequently closed, with Surrozen beginning to trade as a publicly listed company on Nasdaq. Sign up at SpacDesk for full data, filings, and analytics on CHFW and the broader SPAC market.